SEARCH

SEARCH BY CITATION

References

  • 1
    Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 16401645.
  • 2
    Almeda-Valdes P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann. Hepatol. 2009; 8 (Suppl. 1): S1824.
  • 3
    Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124131.
  • 4
    Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 13871395.
  • 5
    Younossi ZM, Stepanova M, Negro F et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012; 91: 319327.
  • 6
    Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J. Hepatol. 2009; 50: 10291034.
  • 7
    Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 163172.
  • 8
    Das K, Das K, Mukherjee PS et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51: 15931602.
  • 9
    Farrell GC, Wong VW, Chitturi S. NAFLD in Asia-as common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 2013; doi: 10.1038/nrgastro.2013.34.
  • 10
    Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis. 2009; 13: 511531.
  • 11
    Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 2009; 8 (Suppl. 1): S4S8.
  • 12
    Wong VW, Wong GL, Choi PC et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969974.
  • 13
    Bedogni G, Miglioli L, Masutti F et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46: 13871391.
  • 14
    Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr. Pharm. Des. 2013 Feb 4 [Epub ahead of print]. doi: 10.2174/13816128113199990336.
  • 15
    Argo CK, Northup PG, Al Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 2009; 51: 371379.
  • 16
    Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113121.
  • 17
    Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008; 40: 14611465.
  • 18
    Pirola CJ, Fernandez GT, Burgueno AL et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2012. DOI: 10.1136/gutjnl-2012-302962.
  • 19
    Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol. 2008; 49: 608612.
  • 20
    Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865873.
  • 21
    Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010; 363: 13411350.
  • 22
    Stefan N, Kantartzis K, Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 2008; 168: 16091616.
  • 23
    White DL, Kanwal F, El Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 2012; 10: 13421359.
  • 24
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S3550.
  • 25
    Savard C, Tartaglione EV, Kuver R et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013; 57: 8192.
  • 26
    Neuschwander-Tetri BA, Wang DQ. Excess cholesterol and fat in the diet: a dangerous liaison for energy expenditure and the liver. Hepatology 2013; 57: 79.
  • 27
    Kalaany NY, Gauthier KC, Zavacki AM et al. LXRs regulate the balance between fat storage and oxidation. Cell Metab. 2005; 1: 231244.
  • 28
    Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774788.
  • 29
    Neuschwander-Tetri BA, Ford DA, Acharya S et al. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012; 47: 941950.
  • 30
    Abdelmalek MF, Suzuki A, Guy C et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 19611971.
  • 31
    Abdelmalek MF, Lazo M, Horska A et al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology 2012; 56: 952960.
  • 32
    Schattenberg JM, Schuchmann M. Diabetes and apoptosis: liver. Apoptosis 2009; 14: 14591471.
  • 33
    Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50: 10941104.
  • 34
    Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J. Nutr. Biochem. 2011; 22: 699711.
  • 35
    Ye D, Li FY, Lam KS et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 2012; 61: 10581067.
  • 36
    Teratani T, Tomita K, Suzuki T et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 2012; 142: 152164.
  • 37
    Machado MV, Cortez-Pinto H. No need for a large belly to have NASH. J. Hepatol. 2011; 54: 10901093.
  • 38
    Rabot S, Membrez M, Bruneau A et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010; 24: 49484959.
  • 39
    Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601609.
  • 40
    Miele L, Valenza V, La Torre G et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 18771887.
  • 41
    Henao-Mejia J, Elinav E, Jin C et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179185.
  • 42
    Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913916.
  • 43
    Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 18831894.
  • 44
    Dubuquoy C, Robichon C, Lasnier F et al. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J. Hepatol. 2011; 55: 145153.
  • 45
    Dubuquoy C, Burnol AF, Moldes M. PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function? Clin. Res. Hepatol. Gastroenterol. 2013; 37: 3035.
  • 46
    Kumari M, Schoiswohl G, Chitraju C et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012; 15: 691702.
  • 47
    Li JZ, Huang Y, Karaman R et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J. Clin. Invest. 2012; 122: 41304144.
  • 48
    Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr. Opin. Lipidol. 2011; 22: 479488.
  • 49
    Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 18981906.
  • 50
    Shen J, Chan HL, Wong GL et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J. Hepatol. 2012; 56: 13631370.
  • 51
    Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 14411447.
  • 52
    Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin. Liver Dis. 2012; 16: 567585.
  • 53
    Kornek M, Lynch M, Mehta SH et al. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology 2012; 143: 448458.
  • 54
    Goodpaster BH, Delany JP, Otto AD et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA 2010; 304: 17951802.
  • 55
    Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G. The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig. Dis. 2010; 28: 267273.
  • 56
    Fealy CE, Haus JM, Solomon TP et al. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J. Appl. Physiol. 2012; 113: 16.
  • 57
    Koh-Banerjee P, Chu NF, Spiegelman D et al. Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men. Am. J. Clin. Nutr. 2003; 78: 719727.
  • 58
    Schattenberg JM, Singh R, Wang Y et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006; 43: 163172.
  • 59
    MacKenzie SH, Schipper JL, Clark AC. The potential for caspases in drug discovery. Curr. Opin. Drug Discov. Devel. 2010; 13: 568576.
  • 60
    Hatting M, Zhao G, Schumacher F et al. Hepatocyte caspase-8 is an essential modulator of steatohepatitis in mice. Hepatology 2013 (in press). DOI: 10.1002/hep.26271.
  • 61
    Anstee QM, Concas D, Kudo H et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J. Hepatol. 2010; 53: 542550.
  • 62
    Ratziu V, Sheikh MY, Sanyal AJ et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012; 55: 419428.
  • 63
    Robson SC, Schuppan D. Adenosine: tipping the balance towards hepatic steatosis and fibrosis. J. Hepatol. 2010; 52: 941943.
  • 64
    Imarisio C, Alchera E, Sutti S et al. Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats. Clin. Sci. (Lond) 2012; 123: 323332.
  • 65
    Peng Z, Borea PA, Varani K et al. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J. Clin. Invest. 2009; 119: 582594.
  • 66
    Stensel D. Exercise, appetite and appetite-regulating hormones: implications for food intake and weight control. Ann. Nutr. Metab. 2010; 57 (Suppl. 2): 3642.
  • 67
    Massa F, Mancini G, Schmidt H et al. Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J. Neurosci. 2010; 30: 62736281.
  • 68
    Holst JJ. Incretin hormones and the satiation signal. Int. J. Obes. (Lond) 2013; DOI: 10.1038/ijo.2012.208.
  • 69
    Balaban YH, Korkusuz P, Simsek H et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann. Hepatol. 2007; 6: 242250.
  • 70
    Miura K, Kitahara Y, Yamagishi S. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats. Horm. Metab. Res. 2010; 42: 731735.
  • 71
    Kern M, Kloting N, Niessen HG et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS ONE 2012; 7: e38744.
  • 72
    Mells JE, Fu PP, Sharma S et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G225235.
  • 73
    Trevaskis JL, Griffin PS, Wittmer C et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G762772.
  • 74
    Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS ONE 2011; 6: e25269.
  • 75
    Nagasawa T, Inada Y, Nakano S et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 2006; 536: 182191.
  • 76
    Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC. Peroxisome proliferator-activated receptor-alpha agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2012; 27: 341350.
  • 77
    Serrano-Marco L, Barroso E, El K I et al. The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia 2012; 55: 743751.
  • 78
    Ratziu V, Giral P, Jacqueminet S et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008; 135: 100110.
  • 79
    Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010; 362: 16751685.
  • 80
    Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011; 34: 20082014.
  • 81
    Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur. J. Pharmacol. 2009; 618: 98104.
  • 82
    Teixeira-Clerc F, Julien B, Grenard P et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 2006; 12: 671676.
  • 83
    Chavez-Tapia NC, Tellez-Avila FI, Bedogni G, Croce LS, Masutti F, Tiribelli C. Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology. BMC Gastroenterol. 2009; 9: 75.
  • 84
    Janero DR, Lindsley L, Vemuri VK, Makriyannis A. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Expert Opin. Drug Discov. 2011; 6: 9951025.
  • 85
    Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 2005; 365: 13631364.
  • 86
    Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today 2012; 17: 988997.
  • 87
    Hollman DA, Milona A, van Erpecum KJ, van Mil SW. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim. Biophys. Acta 2012; 1821: 14431452.
  • 88
    Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 2009; 51: 380388.
  • 89
    Mencarelli A, Cipriani S, Renga B et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS ONE 2012; 7: e45425.
  • 90
    Wagnerberger S, Spruss A, Kanuri G et al. Lactobaccilus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J. Nutr. Biochem. 2013; 24: 531538.
  • 91
    Wong VW, Won GL, Chim AM et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann. Hepatol. 2013; 12: 256262.
  • 92
    Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012; 32: 701711.